Cryptogenic organizing pneumonia epidemiology and demographics: Difference between revisions
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}} | ||
__NOTOC__ | __NOTOC__ | ||
{{Xyz}} | {{Xyz}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
Revision as of 20:40, 15 February 2018
|
Cryptogenic Organizing Pneumonia Microchapters |
|
Differentiating Cryptogenic organizing pneumonia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cryptogenic organizing pneumonia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Cryptogenic organizing pneumonia epidemiology and demographics |
|
FDA on Cryptogenic organizing pneumonia epidemiology and demographics |
|
CDC on Cryptogenic organizing pneumonia epidemiology and demographics |
|
Cryptogenic organizing pneumonia epidemiology and demographics in the news |
|
Blogs on Cryptogenic organizing pneumonia epidemiology and demographics |
|
Directions to Hospitals Treating Cryptogenic organizing pneumonitis |
|
Risk calculators and risk factors for Cryptogenic organizing pneumonia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cryptogenic organizing pneumonia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Cryptogenic organizing pneumonia epidemiology and demographics |
|
FDA on Cryptogenic organizing pneumonia epidemiology and demographics |
|
CDC on Cryptogenic organizing pneumonia epidemiology and demographics |
|
Cryptogenic organizing pneumonia epidemiology and demographics in the news |
|
Blogs on Cryptogenic organizing pneumonia epidemiology and demographics |
|
Risk calculators and risk factors for Cryptogenic organizing pneumonia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Cryptogenic organizing pneumonia commonly affects people of 50-60 years of age.
- Cryptogenic organizing pneumonia rarely affects children.
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Cryptogenic organizing pneumonia]] affects men and women equally.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].